Minerva neurosciences, inc. (NERV)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-12,151

-29,917

-13,962

-12,476

-15,827

-13,202

-12,020

-12,529

-12,418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-10,644

-9,404

-8,423

-5,213

-8,004

-8,439

-5,939

-6,610

-6,093

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,938

Depreciation and amortization

4

4

4

4

4

4

4

4

4

1

2

3

3

3

4

4

4

4

4

-1

9

3

25

4

0

Amortization of debt discount recorded as interest expense

-

-

-

-

-

0

1

12

24

35

46

57

67

76

84

92

94

100

130

79

67

0

3

1,674

274

Accretion of marketable securities premium

64

102

160

258

242

26

9

28

54

102

43

38

1

0

-11

-30

-59

-

-

-

-

-

-

-

-

Amortization of right-of-use assets

38

37

36

35

34

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

2,198

2,169

2,221

2,320

2,461

1,909

2,261

1,897

2,113

1,257

1,233

1,231

1,310

1,012

935

832

790

691

628

545

336

2,246

903

14,514

302

Unrealized foreign exchange gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

Change in fair value of derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4

5

Changes in operating assets and liabilities
Prepaid expenses and other current assets

-330

-194

-76

399

-851

-1,778

470

-1,013

2,944

255

458

-380

-26

100

424

-331

-566

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-194

-253

-

-

-

1

Accounts payable

686

-3,013

2,388

-83

1,225

924

-435

-1,515

1,389

-67

95

-1,867

1,807

635

93

-483

-136

625

170

-332

254

-290

-570

42

1,187

Accrued expenses and other current liabilities

-202

-259

-87

764

1,911

-1,185

684

-81

952

-582

746

-397

857

-165

-472

-1,648

577

300

1,142

-588

26

794

-1,202

580

-60

Operating lease liabilities, current

5

5

5

5

20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued collaborative expenses

-

-

-

-

-

-

-

-

-

0

-6,646

3,567

530

-

-

-

-

-

-

-

-

-

-

-

-

Accrued collaborative expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-383

238

-

-

-

-

Other noncurrent liabilities

-

-

-

-

-

-1

-0

0

0

-

-

-

-

-

-

-

-

0

-2

-2

-2

-

-

-

-

Operating lease liabilities, noncurrent

-46

-45

-44

-42

-41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-9,202

-14,180

-9,521

-10,129

-9,600

-9,799

-9,984

-11,225

-10,931

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Proceeds from the maturity and redemption of marketable securities

20,900

9,334

35,845

21,000

9,000

5,300

29,500

36,101

39,250

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in business combination

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,167

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

40

4

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-6,044

-8,927

-4,656

-6,054

-6,049

-6,602

-5,726

-7,030

-4,909

-5,016

-27,160

-2,544

-1,239

Proceeds from the maturity and redemption of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

8,375

1,400

8,043

-

-

-

-

-

-

-

-

Purchase of marketable securities

3,871

11,646

16,262

13,633

19,551

32,726

0

0

7,934

-

107,187

10,888

16,477

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided (used in) by investing activities

17,028

-2,312

19,582

7,366

-10,551

-27,426

29,500

36,101

31,315

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-16,477

0

8,375

1,400

8,043

4,050

827

-23,202

-4

-46

-33

0

1,167

Proceeds from loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,382

500

Costs paid in connection with public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30

3,024

0

105

Proceeds from sales of common stock in private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

999

0

0

0

30,999

-

-

-

-

Costs paid in connection with private placements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

232

2,234

-

-

-

-

Proceeds from exercise of common stock warrants

-

-

-

-

-

-

-

-

-

0

0

0

9,356

1,169

0

4,678

17,544

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

797

-0

0

0

525

-

-

-

-

0

554

294

281

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

10,000

-

-

-

-

Costs paid in connection with notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

195

-

-

-

-

Repayments of notes payable

-

-

-

-

-

0

1,398

1,312

1,289

1,267

1,245

1,223

1,202

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

797

-0

0

0

525

165

-907

-1,312

-1,289

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

8,623

-16,493

10,061

-2,763

-19,627

-37,061

18,607

23,562

19,093

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash, cash equivalents and restricted cash
Incurred but unpaid private/public placement costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,075

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

0

7

31

53

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

141

162

176

176

176

176

176

176

88

-

-

-

-

Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets
Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,872

3,182

53,848

20,537

-2,552

-4,898

-30,465

33,655

-5,093

23,159

-1,661

322

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

8,436

55

-536

58,503

18,544

0

0

-232

38,569

-30

50,353

882

394

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-14,085

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued as consideration for business combination

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

16,541

Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

321

ProteoSys milestone payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

681

Deferred tax liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,970

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

42

Equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

28

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

15,200

Goodwill

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7,076

Cash acquired in business merger

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,167

Incurred but unpaid private placement costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

238

-

-

-

-

Incurred but unpaid public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,075